2020
Temporal Trends in Arrhythmogenicity Related to Treatment of COVID-19 Infection
Hummel JP, Maraj I, Taoutel R, Chamoun R, Workman VK, Tran L, Abboud JM, Afif C, Chouairi S, Delvecchio A, Howes CJ, Enriquez AD, Akar JG. Temporal Trends in Arrhythmogenicity Related to Treatment of COVID-19 Infection. Circulation Arrhythmia And Electrophysiology 2020, 13: e008841-e008841. PMID: 32931318, PMCID: PMC7566294, DOI: 10.1161/circep.120.008841.Peer-Reviewed Original ResearchIncidence and determinants of QT interval prolongation in COVID‐19 patients treated with hydroxychloroquine and azithromycin
Maraj I, Hummel JP, Taoutel R, Chamoun R, Workman V, Li C, Tran L, DelVecchio A, Howes C, Akar JG. Incidence and determinants of QT interval prolongation in COVID‐19 patients treated with hydroxychloroquine and azithromycin. Journal Of Cardiovascular Electrophysiology 2020, 31: 1904-1907. PMID: 32485061, PMCID: PMC7300464, DOI: 10.1111/jce.14594.Peer-Reviewed Original Research
2018
Periprocedural Use of Oral Anticoagulation Therapy in Patients Undergoing Atrial Fibrillation Ablation
Maraj I, Gonzalez MD, Naccarelli GV. Periprocedural Use of Oral Anticoagulation Therapy in Patients Undergoing Atrial Fibrillation Ablation. Journal Of Innovations In Cardiac Rhythm Management 2018, 9: 3274-3281. PMID: 32477818, PMCID: PMC7252752, DOI: 10.19102/icrm.2018.090801.Peer-Reviewed Original ResearchAtrial fibrillationStroke preventionCatheter ablationLeft atrial appendage occlusion devicesAtrial appendage occlusion devicesRhythm control strategyOral anticoagulation therapyImportant treatment strategyRisk of strokeAtrial fibrillation ablationCommon sustained arrhythmiaLeft atrial appendageClinical practice todayOral anticoagulationPeriprocedural useAnticoagulation therapySurgical exclusionFibrillation ablationSustained arrhythmiaDrug optionsAtrial appendageTreatment strategiesHigh riskOcclusion devicePatientsA Quarter of a Century Later: What is Dofetilide’s Clinical Role Today?
Wolbrette DL, Hussain S, Maraj I, Naccarelli GV. A Quarter of a Century Later: What is Dofetilide’s Clinical Role Today? Journal Of Cardiovascular Pharmacology And Therapeutics 2018, 24: 3-10. PMID: 29940780, DOI: 10.1177/1074248418784288.Peer-Reviewed Original ResearchConceptsAtrial fibrillationAtrial flutterClass III antiarrhythmic agentPost-myocardial infarction patientsAcceptable renal functionAtrioventricular nodal blockadeAcceptable safety profileNormal QT intervalParoxysmal atrial fibrillationReal-world efficacyCreatinine clearanceRenal functionSymptomatic patientsHeart failureAtrial tachycardiaPersistent arrhythmiaSafety profileSinus rhythmAntiarrhythmic agentsInfarction patientsVentricular tachycardiaClinical trialsQT intervalDrug trialsDrug AdministrationPeriprocedural Use of Oral Anticoagulation Therapy in Patients Undergoing Atrial Fibrillation Ablation
Maraj I, Gonzalez MD, Naccarelli GV. J Innov Cardiac Rhythm Manage. 2018;9(8)3274–3281Peer-Reviewed Original ResearchDecrease in Radiation Exposure during Cardiac Implantable Electronic Device (CIED) Implantation with Modern Imaging Platform
Chudow JJ, Maraj I, Zaremski L, Rojas R, Krumerman A, et al. Int J Clin Cardiol Res. 2018;2(3): 072-075Peer-Reviewed Original Research
2017
Role of the left atrial appendage “stump” in persistent atrial fibrillation
Romero J, Briceño DF, Grushko M, Maraj I, Grupposo V, Di Biase L. Role of the left atrial appendage “stump” in persistent atrial fibrillation. HeartRhythm Case Reports 2017, 4: 45-49. PMID: 29876286, PMCID: PMC5988474, DOI: 10.1016/j.hrcr.2017.08.008.Peer-Reviewed Original ResearchLong-term outcomes of different ablation strategies for ventricular tachycardia in patients with structural heart disease: systematic review and meta-analysis
Briceño DF, Romero J, Villablanca PA, Londoño A, Diaz JC, Maraj I, Batul SA, Madan N, Patel J, Jagannath A, Mohanty S, Mohanty P, Gianni C, Della Rocca D, Sabri A, Kim SG, Natale A, Di Biase L. Long-term outcomes of different ablation strategies for ventricular tachycardia in patients with structural heart disease: systematic review and meta-analysis. EP Europace 2017, 20: 104-115. PMID: 28575378, DOI: 10.1093/europace/eux109.Peer-Reviewed Original ResearchConceptsStructural heart diseaseStable ventricular tachycardiaLong-term outcomesVA recurrenceVentricular tachycardiaCause mortalityStandard ablationHeart diseaseExtensive substrate modificationVentricular arrhythmia recurrenceComposite primary outcomeDifferent ablation strategiesIschemic substrateArrhythmia recurrenceIschemic cardiomyopathyPrimary outcomeMAIN OUTCOMESubstrate modificationAblation strategyLower riskElectronic searchPatientsRecurrenceSystematic reviewMortalityVentricular Tachycardia in Ischemic Cardiomyopathy: Are You Certain You Are Ablating the Clinical VT?
Romero J, Briceno DF, Maraj I, Grupposo V, Kim SG, Di Biase L EP Lab Digest 2017 ; 17(5)Peer-Reviewed Original Research
2015
Use of vascular closure device is safe and effective in electrophysiological procedures
Maraj I, Budzikowski AS, Ali W, Mitre CA, Kassotis J. Use of vascular closure device is safe and effective in electrophysiological procedures. Journal Of Interventional Cardiac Electrophysiology 2015, 43: 193-195. PMID: 25921347, DOI: 10.1007/s10840-015-0005-5.Peer-Reviewed Original ResearchConceptsVascular closure deviceClosure deviceElectrophysiological proceduresAccess siteCollagen plug-based vascular closure deviceResultsIn 26 patientsRetrospective chart reviewVascular access sitePeriprocedural anticoagulationChart reviewVenous accessFemoral veinFemoral arteryRetrospective analysisArterial closurePatientsMean numberVeinAnticoagulationEcchymosisComplicationsArteryPurposeLittleGroinVisitsTorsades De Pointes Induced by Methadone and Clonazepam Use
Ashkar A, Goldberg T, Maraj I, Masters A, McFarlane S. Torsades De Pointes Induced by Methadone and Clonazepam Use. International Journal Of Medical And Pharmaceutical Case Reports 2015, 2: 81-85. DOI: 10.9734/ijmpcr/2015/13517.Peer-Reviewed Original Research
2010
Panobinostat, a Novel Histone Deacetylase (HiDAC) Inhibitor Enhances the Anti-Tumor Activity of Bortezomib (BTZ) In Rituximab-Chemotherapy Sensitive and Resistant Lymphoma Cell Lines
Hernandez-Ilizaliturri F, Mavis C, Maraj I, Chisti M, Gibbs J, Czuczman M. Panobinostat, a Novel Histone Deacetylase (HiDAC) Inhibitor Enhances the Anti-Tumor Activity of Bortezomib (BTZ) In Rituximab-Chemotherapy Sensitive and Resistant Lymphoma Cell Lines. Blood 2010, 116: 3936. DOI: 10.1182/blood.v116.21.3936.3936.Peer-Reviewed Original ResearchCell linesBcl-xLBcl-2 family proteinsBcl-2 family membersLymphoma cell linesProteasome inhibitorsRegulation of BakAnti-tumor activityLymphoma cellsB-cell lymphomaCellular processesFamily proteinsWestern blotGene transcriptionPan-caspaseHistone deacetylase inhibitorsSingle agentTarget proteinsCaspase inhibitionMolecular eventsAlamar Blue reductionMcl-1Mitochondrial potentialATP synthesisHodgkin's lymphoma cell lines
2009
The DAC Inhibitor, LBH589, Is Highly Effective in Both Rituximab-Sensitive and Rituximab-Resistant Lymphomas and Enhances the Anti-Tumor Activity of Bortezomib, Other Chemotherapy Agents, and Anti-CD20 Monoclonal Antibodies.
Hernandez-Ilizaliturri F, Marvis C, Maraj I, Chisti M, Gibbs J, Czuczman M. The DAC Inhibitor, LBH589, Is Highly Effective in Both Rituximab-Sensitive and Rituximab-Resistant Lymphomas and Enhances the Anti-Tumor Activity of Bortezomib, Other Chemotherapy Agents, and Anti-CD20 Monoclonal Antibodies. Blood 2009, 114: 2715. DOI: 10.1182/blood.v114.22.2715.2715.Peer-Reviewed Original ResearchPatient-derived primary tumor cellsB-cell lymphomaPrimary tumor cellsChemotherapy agentsAnti-tumor activityMonoclonal antibodiesTumor cellsPolymerase chain reactionLymphoma cell linesCell linesAnti-CD20 Monoclonal AntibodyRoswell Park Cancer InstituteLarge B-cell lymphomaState Cancer CenterCD20 monoclonal antibodySignificant anti-tumor activitySequence of administrationQualitative polymerase chain reactionAnti-tumor effectsPotent treatment strategyNHL cell linesCombination of LBH589Primary lymphoma cellsResistant cell linesSensitive cell linesEfficacy of the DAC inhibitor LBH589 in both rituximab-sensitive and rituximab-resistant lymphomas and effect on the antitumor activity of chemotherapy agents, monoclonal antibodies, and bortezomib
Maraj I, Hernandez-Ilizaliturri F, Chisti M, Czuczman M. Efficacy of the DAC inhibitor LBH589 in both rituximab-sensitive and rituximab-resistant lymphomas and effect on the antitumor activity of chemotherapy agents, monoclonal antibodies, and bortezomib. Journal Of Clinical Oncology 2009, 27: 8576-8576. DOI: 10.1200/jco.2009.27.15_suppl.8576.Peer-Reviewed Original ResearchRituximab-sensitive cell linesRituximab-resistant cell linesCell linesB-cell lymphomaBcl-2 family membersPatient-derived tumor cellsChemotherapy agentsNHL cell linesMonoclonal antibodiesPatient-derived tumour cellsBcl-xL geneCellular processesTumor cellsEffects of LBH589Polymerase chain reactionGene transcriptionGene expressionTarget proteinsAlamar Blue reductionMitochondrial potentialAntitumor activityNegative selectionSequence of administrationQualitative polymerase chain reactionCell titer
2008
The DAC Inhibitor LBH589 Is Highly Effective in Both “Therapy”-Sensitive and -Resistant Lymphomas and Enhances the Anti-Tumor Activity of Chemotherapy Agents, Monoclonal Antibodies, and Bortezomib
Maraj I, Hernandez-Ilizaliturri F, Chisti M, Czuczman M. The DAC Inhibitor LBH589 Is Highly Effective in Both “Therapy”-Sensitive and -Resistant Lymphomas and Enhances the Anti-Tumor Activity of Chemotherapy Agents, Monoclonal Antibodies, and Bortezomib. Blood 2008, 112: 4984. DOI: 10.1182/blood.v112.11.4984.4984.Peer-Reviewed Original ResearchPatient-derived tumour cellsB-cell lymphomaTarget proteinsAnti-tumor activitySequence of administrationNon-histone proteinsChemotherapy agentsCell linesTumor cellsMonoclonal antibodiesCellular processesTranscription factorsEffects of LBH589Gene transcriptionLymphoma cellsAlamar Blue reductionDeacetylasesMitochondrial potentialCell deathRituximab-resistant cell linesSchedule of administrationSignificant anti-tumor activityDAC activityPatient-derived tumor cellsNegative selection